Videos

The chief medical officer at SanBio discussed how the investigational agent SB623 can fill the void of disease-modifying therapies for TBI.

The assistant professor of neurology and anesthesiology at Harvard Medical School discussed non-traditional ways ALS research is changing and where the focus should continue to be.

Neurology News Network for the week ending January 23, 2021.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, also discussed future studies planned for cenobamate.

The associate professor at Hokkaido University and investigator of STEMTRA also discussed other efforts in stroke, Alzheimer disease, and Parkinson disease.

The clinical fellow at Massachusetts General Hospital provided background on his efforts to raise awareness of inconsistencies with EEG education in neurology residency programs.

The AASM board of directors member and professor of medicine at UCLA also discussed the relative inefficacy of sleep hygiene therapy for insomnia.

The director of the Mid-Atlantic Epilepsy and Sleep Center discussed his team’s investigations into predicting responders and adverse events.

The director of the Montefiore Headache Center discussed how his team’s findings can change the way physicians think about treating migraine.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.

The chief medical officer of Cerevel Therapeutics detailed phase 2 data of its investigational agent tavapadon, which has been studied in patients with Parkinson disease.

Neurology News Network for the week ending January 16, 2021.